New epilepsy drug filed for approval

GlaxoSmithKline and Valeant Pharmaceuticals have submitted a marketing authorisation application to the European Medicines Agency for their epilepsy treatment, retigabine.

Retigabine is thought to cause a hyperpolarising shift in the neuronal potassium current and thereby reduce the excitability of neuronal cells.
Retigabine is thought to cause a hyperpolarising shift in the neuronal potassium current and thereby reduce the excitability of neuronal cells.

The companies are seeking approval for retigabine as an adjunctive treatment in adults with refractory partial-onset seizures. If approved, the drug would be the first in a new class of neuronal potassium channel openers.

Retigabine has been evaluated in two randomised, double-blind, placebo-controlled Phase III trials in patients receiving up to three antiepileptic medications. The drug met its primary efficacy end points at all doses tested.

RESTORE 1 enrolled 306 patients to receive either retigabine 1200mg daily in three divided doses, or placebo. The study lasted for a total of 32 weeks and a response to treatment was defined as a reduction of at least 50% in 28-day total partial seizure frequency during the maintenance phase.

In the intention to treat analysis, the rate of response in the retigabine group (55.5%) was more than twice as high as that in the placebo group (22.6%).

RESTORE 2 tested 600mg and 900mg divided daily doses of retigabine in a total of 539 patients over 30 weeks. As in RESTORE 1, the proportion of patients who achieved a response was significantly greater in the retigabine groups than in the placebo group.

The adverse effects most commonly associated with retigabine in the RESTORE trials included dizziness, somnolence, fatigue, confusion, slurring of speech, ataxia, blurred vision, tremor, and nausea.

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases